Issue: July 25, 2018
June 19, 2018
1 min read

Roswell Park Comprehensive Cancer Center researcher receives award to study kidney cancer vaccine

Issue: July 25, 2018
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

John Ebos, PhD, of the department of pharmacology and therapeutics at Roswell Park Comprehensive Cancer Center received a $792,000 multiyear research grant from American Cancer Society.

Patients with metastatic kidney cancer often stop treatment when their tumor becomes resistant to the therapies they are receiving.

Ebos is studying a vaccine designed to inhibit the tumor growth that often happens when treatment has stopped. If proven effective, this could provide additional time for patients and providers to identify new treatment options.

“The American Cancer Society research grant has changed the momentum of my work, providing financial stability for my lab and allowing me to find answers to questions we have been asking for more than 10 years,” Ebos said in a press release.

The cancer society provided 110 national research and training grants totaling more than $47.6 million. The grants, which will take effect July 1, will fund investigators at 72 institutions across the country.